Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $98.39

Gilead Sciences, Inc. (NASDAQ:GILD) has received an average rating of “Moderate Buy” from the twenty-seven analysts that are covering the firm, Marketbeat reports. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $98.39.

GILD has been the topic of a number of research analyst reports. Oppenheimer increased their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last quarter. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GILD. Algert Global LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $254,000. Quarry LP bought a new position in Gilead Sciences in the second quarter valued at about $43,000. Centaurus Financial Inc. boosted its position in Gilead Sciences by 12.4% in the second quarter. Centaurus Financial Inc. now owns 4,798 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 529 shares during the last quarter. AMF Tjanstepension AB grew its stake in shares of Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after purchasing an additional 51,390 shares during the period. Finally, Czech National Bank increased its position in shares of Gilead Sciences by 6.8% during the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company’s stock valued at $21,263,000 after purchasing an additional 16,209 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 2.0 %

GILD stock opened at $96.04 on Monday. The company’s 50 day moving average is $93.04 and its 200 day moving average is $86.76. The stock has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $100.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.